217 related articles for article (PubMed ID: 22318901)
1. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.
Novelli EM; Kato GJ; Ragni MV; Zhang Y; Hildesheim ME; Nouraie M; Barge S; Meyer MP; Hassett AC; Gordeuk VR; Gladwin MT; Isenberg JS
Am J Hematol; 2012 Mar; 87(3):326-30. PubMed ID: 22318901
[TBL] [Abstract][Full Text] [Related]
2. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
5. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
Barbu EA; Dominical VM; Mendelsohn L; Thein SL
PLoS One; 2019; 14(12):e0226583. PubMed ID: 31869367
[TBL] [Abstract][Full Text] [Related]
6. [How I treat ... sickle cell anemia: current therapies].
Rezaei Kalantari H
Rev Med Liege; 2001 Oct; 56(10):671-5. PubMed ID: 11765575
[TBL] [Abstract][Full Text] [Related]
7. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
[TBL] [Abstract][Full Text] [Related]
9. Chronic osteo-articular changes in patients with sickle cell disease.
Ferreira TFA; Dos Santos APT; Leal AS; de Araújo Pereira G; Silva SS; Moraes-Souza H
Adv Rheumatol; 2021 Feb; 61(1):11. PubMed ID: 33608055
[TBL] [Abstract][Full Text] [Related]
10. Sickle cell disease clinical phenotypes in children from South-Western, Nigeria.
Adegoke SA; Adeodu OO; Adekile AD
Niger J Clin Pract; 2015; 18(1):95-101. PubMed ID: 25511352
[TBL] [Abstract][Full Text] [Related]
11. Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.
Belini Junior E; Silva DG; Torres Lde S; Okumura JV; Lobo CL; Bonini-Domingos CR
Blood Cells Mol Dis; 2015 Apr; 54(4):321-7. PubMed ID: 25842370
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
13. Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Brandow AM; Wandersee NJ; Dasgupta M; Hoffmann RG; Hillery CA; Stucky CL; Panepinto JA
Br J Haematol; 2016 Oct; 175(2):237-245. PubMed ID: 27539682
[TBL] [Abstract][Full Text] [Related]
14. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
15. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
[TBL] [Abstract][Full Text] [Related]
16. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
[TBL] [Abstract][Full Text] [Related]
17. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study.
Lemonne N; Möckesch B; Charlot K; Garnier Y; Waltz X; Lamarre Y; Antoine-Jonville S; Etienne-Julan M; Hardy-Dessources MD; Romana M; Connes P
Clin Hemorheol Microcirc; 2017; 67(2):141-148. PubMed ID: 28759962
[TBL] [Abstract][Full Text] [Related]
18. Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease.
Elbarbary NS; Ismail EA; Roushdy A; Fahmy E
Blood Cells Mol Dis; 2016 Mar; 57():1-7. PubMed ID: 26852648
[TBL] [Abstract][Full Text] [Related]
19. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
[TBL] [Abstract][Full Text] [Related]
20. Lactate dehydrogenase isoenzyme 3 and hemolysis in sickle cell anemia: a possible correlation?
Mecabo G; Yamamoto M; Biassi TP; Figueiredo MS
Blood; 2015 Jun; 125(24):3821-2. PubMed ID: 26069337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
